Oppenheimer & Co’s BioAtla BCAB Stock Holding History

Oppenheimer & Co’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-117	Closed	-$247K	–	1490
2021 Q2	$247K	Hold	117	–	–	﹤0.01%	1341
2021 Q1	$297K	Buy	+117	New	+$300K	0.01%	1186

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Oppenheimer & Co's BCAB Position: Q3 2021 in Review

Oppenheimer & Co sold out of BioAtla (BCAB) in Q3 2021, closing a stake of 117 shares — an estimated $247K sold.

Oppenheimer & Co first reported a position in BCAB in Q1 2021 and held it in 2 quarters. The position peaked at $297K in Q1 2021. 86 funds tracked by Wall St. Rank hold BCAB as of Q3 2021.

Oppenheimer & Co reported no remaining BioAtla position as of Q3 2021 after selling out during the quarter.
Oppenheimer & Co sold 117 BioAtla shares in Q3 2021, an estimated $247K.
Oppenheimer & Co first reported a position in BioAtla in Q1 2021 and held it in 2 quarters.
Oppenheimer & Co's BioAtla position peaked at $297K in Q1 2021.
86 funds tracked by Wall St. Rank held BioAtla as of Q3 2021.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.